The test has a sensitivity of 88.2% in detecting cancers of all stages and types. Additionally, it has an accuracy of 93.1% in determining the tissue or organ of origin in  positive cases. This means that even early-stage cancers are reliably detected. Additionally, the specificity of Trucheck is 96.3% in asymptomatic individuals and 95% in individuals with benign tumors.

The test will give a negative or positive result. A negative result suggests that no circulating tumor cells were detected in the donated blood sample. A positive result occurs when CTCs are detected in the donated blood sample, suggesting malignancy with a sensitivity of 99.9%. This can be further analyzed to determine the tissue or organ of origin.

In certain circumstances, an imbalance in the composition of the microbiota can manifest itself, characterized by an excessive or insufficient presence of certain bacteria compared to normal, which is called dysbiosis.

Evidence suggests that this disruption of the balance of the intestinal microbiota could be linked to problems such as depression, obesity, chronic inflammatory diseases, Alzheimer's, Parkinson's or certain cancers.

Maintaining the balance of the intestinal microbiota is therefore of crucial importance for:

Guarantee the proper functioning of its various functions.
Limit its involvement in the development of metabolic, digestive, and other pathologies.

In order to achieve this objective, it is essential to know the composition of one's microbiota to detect possible imbalances and identify the possible presence of pathogens. With this in mind, we offer you the “intestinal microbiota” assessment, which allows you to establish a detailed map of your intestinal microbiota.

Nearly one in two people will be diagnosed with cancer in their lifetime and 50% of these people will be diagnosed after their cancer has spread significantly.

Cancer is the leading cause of premature mortality in France, ahead of cardiovascular diseases. In 2023, it is estimated that more than 433,136 new cases of cancer will be diagnosed in France and that 3.8 million people live in France today with a cancer diagnosis.

The goal of screening is to be able to diagnose cancer at an early stage, even if it does not yet produce symptoms. Very early treatment promotes the chances of recovery and limits the after-effects linked to the disease and certain treatments.

The test is reserved for asymptomatic adult men and women without a prior cancer diagnosis and over the age of 35.

Datar Cancer Genetics is a global oncology research and applications company that is at the forefront of developing non-invasive technologies to improve the detection, treatment and management of cancer. The company's state-of-the-art cancer research center is NABL, ISO, CAP and CLIA accredited. The company serves cancer patients and suspected cases in the UK, EU, US, GCC and India. The company has modern cancer research facilities in the United States, United Kingdom and India.

The test is already available in Europe under the name Trucheck and carries the CE mark.

A positive result means that CTCs have been found in your blood. The test results will indicate the location of the selected cancer type with high accuracy, and in other cancers the tissue of origin can be identified with reasonable accuracy. This means we can tell you where the cancer started to grow in your body.

If you test positive, your doctor will personally call you to discuss your results, what they mean, and guide you in your next steps, including a referral. We have established a patient pathway if you get a positive result.

A negative result means that at the time of the test, there were no detectable cancer cells for the cancers included in the test circulating in your blood. This doesn't mean you'll never develop cancer. For all cancers not covered by the test, no conclusions should be drawn from a negative result.

Sensitivity is the ability to correctly identify people with cancer. All TruCheck tests detect early signs of cancer at least 88% of the time. So the test will correctly identify at least 88 out of 100 people with early signs of cancer.

Body CheckUp is a subsidiary of Kensington International Clinic (https://kensingtoninternationalclinic.co.uk/en/)

Located in the Kensington district of London, Kensington International Clinic (La Maison Médicale) is an international clinic created by a group of French doctors in 2010 and which includes a complete health center and 3 centers of excellence: gastrointestinal, gynecology, mental health and well-being. The clinic has more than 40 doctors and has welcomed nearly 20,000 patients. The clinic created the KIC ACADEMY which works in particular in the field of microbiota and preventive detection of cancers. La Maison Médicale has become a pioneer in these exciting areas of medicine, offering very effective diagnostic and treatment programs specifically adapted to each patient.

Specificity is the ability to correctly identify people who do not have cancer.

All TruCheck tests have a specificity of 99%. So the test will correctly identify 99 out of 100 people without cancer. This means you have a low probability of receiving a false positive result and undergoing unnecessary medical procedures.

Certain clinical requirements must be met in order to be eligible for this test.

Before registering, a pre-consultation call with our doctor will be arranged.

To take this test, you must:

Be aged 40 or over. (People aged 35-40 are accepted subject to being considered high risk, please inquire)
Currently have no symptoms of cancer. If you have suspicious symptoms, you should consult your GP urgently.
Do not currently have any clinical or radiological suspicion of cancer.
Have never been diagnosed with any cancer.
Have never received treatment for any type of cancer.
Do not receive a blood transfusion within 72 hours before your blood test appointment.

Sample tubes contain an additive or activator that must be mixed gently with the sample, to ensure sample stability.
The sample will remain stable during transport. It must be returned to the laboratory on the same day of collection. We have taken every precaution and tested different shipping conditions and temperature variations to ensure that the samples remain intact during transport to the laboratory.
In the rare event that there are transport delays or extreme temperatures and your sample cannot be tested by the laboratory, you will be contacted and our customer team will arrange for a new test kit to be sent out.

Included in the price is the test kit, home delivery, the DHL return envelope, the test report and an interview with a specialized doctor in the event of positive results who will be able to guide you towards the best protocol.

Not included in the test: The blood test to be carried out in the laboratory of your choice.

As this early cancer detection test is non-invasive, there is no downside to frequent testing. However, we advise carrying out this test every 12 months in the case of each negative result, perhaps as part of an annual comprehensive health check process.

-TruCheck detects the existence of cancers and not the possibility of cancers

- Conventional means of detecting cancer (mammography, colonoscopy, etc.) should still be favored

- A negative response to this test does not mean that you are free from any possibility of getting cancer

- TruCheck is not a substitute for medical diagnosis or treatment

The security of your data is of the utmost importance to us. We use appropriate technical and organizational measures to ensure the security and confidentiality of your information, and only share your information when necessary to provide our products and services or when we have a legal basis to do so. All samples are discarded after analysis.

For more information about our privacy and security practices, please review our Privacy Policy and Terms and Conditions or feel free to contact our Data Protection Officer at t.derville@Bodycheckup.com